Evonik says new active pharmaceutical ingredient (API) plant in China is part of horizontal integration strategy.
The current good manufacturing practice (cGMP) compliant facility, in Nanning in Guanxi province, will supply an unnamed European company that collaborated on development of the site.
Evonik Rexim, the subsidiary that will run day-to-day operations at the facility, will also produce API for China’s rapidly expanding drug manufacturing sector.
Hans-Josef Ritzert, who head up Evonik's $1b exclusive synthesis business said: "The new plant is an expression of our horizontal integration strategy," explaining that "horizontal integration" stands for a network of western and Asian production sites.
"With this plant we will further consolidate our position as a high performing partner for exclusive synthesis," added Ritzert.